Search Results

AviadoBio today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients in the United States at The Ohio State University.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

PAVmed Inc. announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform™.

Bruker Corporation announced the successful installation of a 1.2 Gigahertz NMR system at the National Gateway Ultrahigh Field NMR Center at The Ohio State University.

BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) (“BioVaxys” or “the Company”), is pleased to announce that it has further extended its research collaboration with The Ohio State University (“The Ohio State”) for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization, is collaborating with The Ohio State University Gene Therapy Institute for the development and clinical manufacturing of novel gene therapies.

The Company will utilize its proprietary induced pluripotent stem cell (iPSC)-derived NK cells to conduct the evaluation. Subject to the results, Cartherics will then exercise the option to negotiate a commercial license to the IP.

Amgen announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.